(Q36407480)

14 August 2017

1 reference

title

Review of clinical radioimmunotherapy (English)

1 reference

14 August 2017

Brad Pohlman

1

1 reference

14 August 2017

John Sweetenham

series ordinal

2

1 reference

14 August 2017

Roger M Macklis

series ordinal

3

1 reference

14 August 2017

publication date

1 March 2006

1 reference

Expert Review of Anticancer Therapy

14 August 2017

published in

1 reference

14 August 2017

volume

6

1 reference

14 August 2017

issue

3

1 reference

14 August 2017

page(s)

445-461

1 reference

Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

Dosimetry and treatment planning for 90Y-labeled antiferritin in hepatoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

Low-dose hypersensitivity: current status and possible mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

Store-operated cation entry mediated by CD20 in membrane rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

The radioisotope contributes significantly to the activity of radioimmunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

131I-tositumomab therapy as initial treatment for follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

Use of Radiolabeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.445

21 January 2018

Identifiers

DOI

10.1586/14737140.6.3.445

1 reference

release_wrulxzom55f7tjqrhpvuqdx4sm

14 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wrulxzom55f7tjqrhpvuqdx4sm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference